N-(2-氨基苯基)-4-[1-[2-(3-噻吩基)乙基]-1H-1,2,3-三唑-4-基]苯甲酰胺 | 1451042-18-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(2-氨基苯基)-4-[1-[2-(3-噻吩基)乙基]-1H-1,2,3-三唑-4-基]苯甲酰胺
• 英文名称: N-(2-aminophenyl)-4-[1-(2-thiophen-3-ylethyl)-1H-[1],[2],[3]-triazol-4-yl]benzamide
• 英文别名: N-(2-aminophenyl)-4-[1-(2-thiophen-3-ylethyl)-1H-[1,2,3]triazol-4-yl]benzamide；N-(2-aminophenyl)-4-[1-(2-thiophen-3-ylethyl)-1H-1,2,3triazol-4-yl]benzamide；T247；N-(2-Aminophenyl)-4-[1-[2-(3-thienyl)ethyl]-1H-1,2,3-triazol-4-yl]benzamide；N-(2-aminophenyl)-4-[1-(2-thiophen-3-ylethyl)triazol-4-yl]benzamide
• CAS: 1451042-18-4
• 化学式: C₂₁H₁₉N₅OS
• 分子量: 389.481
• InChiKey: LBLSLSOENGWIHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  噻吩-3-乙醇 在 sodium azide 、 copper(ll) sulfate pentahydrate 、 sodium ascorbate 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 生成 N-(2-氨基苯基)-4-[1-[2-(3-噻吩基)乙基]-1H-1,2,3-三唑-4-基]苯甲酰胺
  参考文献：
  名称：

  [EN] ISOFORM-SELECTIVE LYSINE DEACETYLASE INHIBITORS
  [FR] INHIBITEURS DE LYSINE DÉSACÉTYLASE SÉLECTIFS ENVERS LES ISOFORMES

  摘要：

  描述了选择性异构体赖氨酸去乙酰化酶抑制剂。赖氨酸去乙酰化酶的抑制剂可用作抗肿瘤药物，治疗成瘾、哮喘、心血管疾病、免疫抑制、神经退行性疾病、败血症、镰刀细胞病、葡萄膜黑色素瘤以及终止病毒潜伏，尤其是HIV-1潜伏。

  公开号：

  WO2016179398A1

文献信息

• RESIN COMPOSITION, LAMINATE, RESIN COMPOSITION LAYER-ATTACHED SEMICONDUCTOR WAFER, SUBSTRATE FOR MOUNTING RESIN COMPOSITION LAYER-ATTACHED SEMICONDUCTOR, AND SEMICONDUCTOR DEVICE
  申请人：MITSUBISHI GAS CHEMICAL COMPANY, INC.

  公开号：EP3786200A1

  公开（公告）日：2021-03-03

  A resin composition that has excellent flux activity, flexibility and storage stability and that is suitable for a pre-applied underfill material is provided. The resin composition of the present invention contains a compound (A) having a phenolic hydroxy group, a metal ion trapping agent (B) and a radical polymerizable compound (C).

  本发明提供了一种树脂组合物，该树脂组合物具有优异的通量活性、柔韧性和贮存稳定性，适用于预涂敷的底部填充材料。本发明的树脂组合物含有一种具有酚羟基的化合物（A）、一种金属离子捕获剂（B）和一种可自由基聚合的化合物（C）。
• Isoform-selective lysine deacetylase inhibitors
  申请人：WASHINGTON UNIVERSITY

  公开号：US10421778B2

  公开（公告）日：2019-09-24

  Isoform-selective lysine deacetylase inhibitors are described. Inhibitors of the lysine deacetylase enzyme are useful as antitumor drugs and for treating addiction, asthma, cardio-vascular disease, immunosuppression, neurodegenerative diseases, sepsis, sickle-cell disease, uveal melanoma and termination of viral latency, particularly HIV-1 latency.

  介绍了具有同工酶选择性的赖氨酸脱乙酰酶抑制剂。赖氨酸去乙酰化酶抑制剂可用作抗肿瘤药物和治疗成瘾、哮喘、心血管疾病、免疫抑制、神经退行性疾病、败血症、镰状细胞病、葡萄膜黑色素瘤和终止病毒潜伏期，特别是 HIV-1 潜伏期。
• Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors
  作者：Damodara N. Reddy、Flavio Ballante、Timothy Chuang、Adele Pirolli、Biagina Marrocco、Garland R. Marshall

  DOI：10.1021/acs.jmedchem.5b01632

  日期：2016.2.25

  Selective inhibition of KDAC isoforms while maintaining potency remains a challenge. Using the largazole macrocyclic depsipeptide structure as a starting point for developing new KDACIs with increased selectivity, a combination of four different simplified largazole analogue (SLA) scaffolds with diverse zinc-binding groups (for a total of 60 compounds) were designed, synthesized, and evaluated against class I KDACs 1, 3, and 8, and class II KDAC6. Experimental evidence as well as molecular docking poses converged to establish the cyclic tetrapeptides (CTPs) as the primary determinant of both potency and selectivity by influencing the correct alignment of the zinc-binding group in the KDAC active site, providing a further basis for developing new KDACIs of higher isoform selectivity and potency.
• METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE
  申请人：Design Therapeutics, Inc.

  公开号：US20210238226A1

  公开（公告）日：2021-08-05

  The present disclosure relates to compounds and methods for modulating the expression of dmpk, atxn1, atxn2, atxn3, cacna1a, atxn7, ppp2r2br tbp, htt, jph3r ar, or atn1 and treating diseases and conditions in which dmpk, atxn1, atxn2, atxn3, cacna1a, atxn1, ppp2r2b, tbp, htt, jph3, ar, or atn1 plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.
• RESIN COMPOSITION, LAMINATE, SEMICONDUCTOR WAFER WITH RESIN COMPOSITION LAYER, SUBSTRATE FOR MOUNTING SEMICONDUCTOR WITH RESIN COMPOSITION LAYER AND SEMICONDUCTOR DEVICE
  申请人：MITSUBISHI GAS CHEMICAL COMPANY, INC.

  公开号：US20210277221A1

  公开（公告）日：2021-09-09

  A resin composition that has excellent flux activity, flexibility and storage stability and that is suitable for a pre-applied underfill material is provided. The resin composition contains a compound (A) having a phenolic hydroxy group, a metal ion trapping agent (B) and a radical polymerizable compound (C).